SCHEMBL23499574

SCHEMBL23499574

CC12OC(CC1(O)C(=O)OCCCCCS(=O)(=O)CC1CS1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMTK3 Q96Q04 2/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
PDK1 Q15118 1/20 0.78
NTRK1 P04629 8/20 0.67
PRKCQ Q04759 7/20 0.67
KDR P35968 7/20 0.67
PRKD3 O94806 5/20 0.67
PRKCA P17252 5/20 0.67
PRKCH P24723 5/20 0.67
PRKCI P41743 5/20 0.67
PRKCE Q02156 5/20 0.67
PRKCD Q05655 5/20 0.67
PRKD1 Q15139 5/20 0.67
MAP3K11 Q16584 5/20 0.67
PRKCG P05129 4/20 0.67
PRKCB P05771 4/20 0.67
PRKCZ Q05513 4/20 0.67
MYLK Q15746 4/20 0.67
MAP3K9 P80192 4/20 0.67
MAP3K10 Q02779 4/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13169944 0.88 LMTK3 (1.00) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
SCHEMBL5951557 0.88 LMTK3 (1.00) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
SCHEMBL29394491 0.88 LMTK3 (1.00) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
SCHEMBL24393927 0.88 LMTK3 (1.00) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
SCHEMBL16112156 0.88 LMTK3 (1.00) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
SCHEMBL31119069 0.88 LMTK3 (1.00) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
SCHEMBL20865173 0.85 LMTK3 (0.85) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
SCHEMBL20865167 0.83 LMTK3 (0.81) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
SCHEMBL20865155 0.82 LMTK3 (0.79) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ
K-252A SCHEMBL24112155 0.81 NTRK1 (1.00) LMTK3SMN1; SMN2PDK1NTRK1PRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021119183-A1 TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES 712 NORTH, INC. (US) 2021-06-17 WO claimed
US-20230065809-A1 TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES 712 NORTH INC. 2023-03-02 US disclosed
WO-2021119183-A1 TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES 712 NORTH, INC. (US) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065809-A1 TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES OPA1, OLA1, ACOX1 LMTK3 3006/4885SMN1; SMN2 2071/4885PDK1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.